Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma.

Faict S, Oudaert I, D'Auria L, Dehairs J, Maes K, Vlummens P, De Veirman K, De Bruyne E, Fostier K, Vande Broek I, Schots R, Vanderkerken K, Swinnen JV, Menu E.

Cancers (Basel). 2019 Nov 20;11(12). pii: E1823. doi: 10.3390/cancers11121823.

2.

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.

Maes A, Maes K, Vlummens P, De Raeve H, Devin J, Szablewski V, De Veirman K, Menu E, Moreaux J, Vanderkerken K, De Bruyne E.

Blood Cancer J. 2019 Nov 18;9(12):87. doi: 10.1038/s41408-019-0249-x.

3.

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.

Yan S, Vandewalle N, De Beule N, Faict S, Maes K, De Bruyne E, Menu E, Vanderkerken K, De Veirman K.

Cancers (Basel). 2019 Nov 5;11(11). pii: E1727. doi: 10.3390/cancers11111727. Review.

4.

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma.

Vlummens P, De Veirman K, Menu E, De Bruyne E, Offner F, Vanderkerken K, Maes K.

Front Genet. 2019 Aug 15;10:740. doi: 10.3389/fgene.2019.00740. eCollection 2019. Review.

5.

Dynamics of Vaginal and Rectal Microbiota Over Several Menstrual Cycles in Female Cynomolgus Macaques.

Nugeyre MT, Tchitchek N, Adapen C, Cannou C, Contreras V, Benjelloun F, Ravel J, Le Grand R, Marlin R, Menu E.

Front Cell Infect Microbiol. 2019 Jun 12;9:188. doi: 10.3389/fcimb.2019.00188. eCollection 2019.

6.

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.

Maes A, Maes K, De Raeve H, De Smedt E, Vlummens P, Szablewski V, Devin J, Faict S, De Veirman K, Menu E, Offner F, Spaargaren M, Moreaux J, Vanderkerken K, Van Valckenborgh E, De Bruyne E.

Br J Cancer. 2019 Jun;120(12):1137-1146. doi: 10.1038/s41416-019-0471-0. Epub 2019 May 15.

PMID:
31089208
7.

Seminal Plasma Exposures Strengthen Vaccine Responses in the Female Reproductive Tract Mucosae.

Marlin R, Nugeyre MT, Tchitchek N, Parenti M, Lefebvre C, Hocini H, Benjelloun F, Cannou C, Nozza S, Dereuddre-Bosquet N, Levy Y, Barré-Sinoussi F, Scarlatti G, Le Grand R, Menu E.

Front Immunol. 2019 Mar 12;10:430. doi: 10.3389/fimmu.2019.00430. eCollection 2019.

8.

A hospital qPCR-based survey of 10 gastrointestinal parasites in routine diagnostic screening, Marseille, France.

Menu E, Mary C, Toga I, Raoult D, Ranque S, Bittar F.

Epidemiol Infect. 2019 Jan;147:e100. doi: 10.1017/S0950268819000165.

9.

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response.

De Smedt E, Lui H, Maes K, De Veirman K, Menu E, Vanderkerken K, De Bruyne E.

Front Oncol. 2018 Dec 11;8:566. doi: 10.3389/fonc.2018.00566. eCollection 2018. Review.

10.

Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.

De Veirman K, Menu E, Maes K, De Beule N, De Smedt E, Maes A, Vlummens P, Fostier K, Kassambara A, Moreaux J, Van Ginderachter JA, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Cancer Lett. 2019 Feb 1;442:233-241. doi: 10.1016/j.canlet.2018.11.002. Epub 2018 Nov 9.

PMID:
30419344
11.

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.

Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, Heusschen R, De Raeve H, Schots R, Vanderkerken K, Caers J, Menu E.

Blood Cancer J. 2018 Nov 8;8(11):105. doi: 10.1038/s41408-018-0139-7.

12.

The genetic landscape of 5T models for multiple myeloma.

Maes K, Boeckx B, Vlummens P, De Veirman K, Menu E, Vanderkerken K, Lambrechts D, De Bruyne E.

Sci Rep. 2018 Oct 9;8(1):15030. doi: 10.1038/s41598-018-33396-w.

13.

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects.

De Beck L, Melhaoui S, De Veirman K, Menu E, De Bruyne E, Vanderkerken K, Breckpot K, Maes K.

Oncoimmunology. 2018 Jul 23;7(10):e1484981. doi: 10.1080/2162402X.2018.1484981. eCollection 2018.

14.

Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function?

Venken K, Favreau M, Gaublomme D, Menu E, Vanderkerken K, Elewaut D.

Mol Immunol. 2018 Sep;101:521-526. doi: 10.1016/j.molimm.2018.08.019. Epub 2018 Aug 25. Review.

PMID:
30153633
15.

Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

De Beule N, Menu E, Bertrand MJM, Favreau M, De Bruyne E, Maes K, De Veirman K, Radwanska M, Samali A, Magez S, Vanderkerken K, De Trez C.

Oncotarget. 2018 Apr 27;9(32):22871. doi: 10.18632/oncotarget.25336. eCollection 2018 Apr 27.

16.

Metabolic Features of Multiple Myeloma.

El Arfani C, De Veirman K, Maes K, De Bruyne E, Menu E.

Int J Mol Sci. 2018 Apr 14;19(4). pii: E1200. doi: 10.3390/ijms19041200. Review.

17.

Evaluation of two DNA extraction methods for the PCR-based detection of eukaryotic enteric pathogens in fecal samples.

Menu E, Mary C, Toga I, Raoult D, Ranque S, Bittar F.

BMC Res Notes. 2018 Mar 27;11(1):206. doi: 10.1186/s13104-018-3300-2.

18.

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, Robert N, Heirman C, Cakana A, Hose D, Breckpot K, van Grunsven LA, De Veirman K, Menu E, Vanderkerken K, Moreaux J, De Bruyne E.

Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19.

19.

The therapeutic potential of cell cycle targeting in multiple myeloma.

Maes A, Menu E, Veirman K, Maes K, Vand Erkerken K, De Bruyne E.

Oncotarget. 2017 Jun 28;8(52):90501-90520. doi: 10.18632/oncotarget.18765. eCollection 2017 Oct 27. Review.

20.

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E.

Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13.

21.

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

De Beule N, Menu E, Bertrand MJM, Favreau M, De Bruyne E, Maes K, De Veirman K, Radwanska M, Samali A, Magez S, Vanderkerken K, De Trez C.

Oncotarget. 2017 May 24;8(32):52016-52025. doi: 10.18632/oncotarget.18152. eCollection 2017 Aug 8. Erratum in: Oncotarget. 2018 Apr 27;9(32):22871.

22.

Modified Vaccinia Virus Ankara Vector Induces Specific Cellular and Humoral Responses in the Female Reproductive Tract, the Main HIV Portal of Entry.

Marlin R, Nugeyre MT, Tchitchek N, Parenti M, Hocini H, Benjelloun F, Cannou C, Dereuddre-Bosquet N, Levy Y, Barré-Sinoussi F, Scarlatti G, Le Grand R, Menu E.

J Immunol. 2017 Sep 1;199(5):1923-1932. doi: 10.4049/jimmunol.1700320. Epub 2017 Jul 31.

23.

Molecular mechanisms, current management and next generation therapy in myeloma bone disease.

Heusschen R, Muller J, Duray E, Withofs N, Bolomsky A, Baron F, Beguin Y, Menu E, Ludwig H, Caers J.

Leuk Lymphoma. 2018 Jan;59(1):14-28. doi: 10.1080/10428194.2017.1323272. Epub 2017 Jun 2. Review.

PMID:
28573897
24.

First case of B ALL with KMT2A-MAML2 rearrangement: a case report.

Menu E, Beaufils N, Usseglio F, Balducci E, Lafage Pochitaloff M, Costello R, Gabert J.

BMC Cancer. 2017 May 23;17(1):363. doi: 10.1186/s12885-017-3368-4.

25.

Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma.

Favreau M, Menu E, Gaublomme D, Vanderkerken K, Faict S, Maes K, De Bruyne E, Govindarajan S, Drennan M, Van Calenbergh S, Leleu X, Zabeau L, Tavernier J, Venken K, Elewaut D.

Leukemia. 2017 Dec;31(12):2678-2685. doi: 10.1038/leu.2017.146. Epub 2017 May 11.

PMID:
28490813
26.

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition.

Favreau M, Venken K, Faict S, Maes K, De Veirman K, De Bruyne E, Leleu X, Boon L, Elewaut D, Vanderkerken K, Menu E.

Haematologica. 2017 Jul;102(7):e266-e270. doi: 10.3324/haematol.2017.163758. Epub 2017 Apr 6. No abstract available.

27.

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.

De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van Valckenborgh E, Vanderkerken K.

J Pathol. 2017 Mar;241(4):534-546. doi: 10.1002/path.4860. Epub 2017 Jan 30.

PMID:
27976373
28.

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.

Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots R, Vanderkerken K, Menu E.

Oncotarget. 2016 Jun 21;7(25):38927-38945. doi: 10.18632/oncotarget.7792. Review.

29.

Evaluation of empirical treatment for blood culture-negative endocarditis.

Menu E, Gouriet F, Casalta JP, Tissot-Dupont H, Vecten M, Saby L, Hubert S, Salaun E, Theron A, Grisoli D, Lavoute C, Collart F, Habib G, Raoult D.

J Antimicrob Chemother. 2017 Jan;72(1):290-298. Epub 2016 Sep 27.

PMID:
27678286
30.

NK cells control HIV-1 infection of macrophages through soluble factors and cellular contacts in the human decidua.

Quillay H, El Costa H, Duriez M, Marlin R, Cannou C, Madec Y, de Truchis C, Rahmati M, Barré-Sinoussi F, Nugeyre MT, Menu E.

Retrovirology. 2016 Jun 6;13(1):39. doi: 10.1186/s12977-016-0271-z.

31.

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Bieghs L, Johnsen HE, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, Nyegaard M, Conover CA, Vanderkerken K, De Bruyne E.

Oncotarget. 2016 Jul 26;7(30):48732-48752. doi: 10.18632/oncotarget.8982. Review.

32.

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.

De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, Van Riet I.

Cancer Lett. 2016 Jul 10;377(1):17-24. doi: 10.1016/j.canlet.2016.04.024. Epub 2016 Apr 19.

PMID:
27102001
33.

SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.

Heusschen R, Muller J, Binsfeld M, Marty C, Plougonven E, Dubois S, Mahli N, Moermans K, Carmeliet G, Léonard A, Baron F, Beguin Y, Menu E, Cohen-Solal M, Caers J.

Oncotarget. 2016 May 24;7(21):30712-29. doi: 10.18632/oncotarget.8750.

34.

A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.

Rasche L, Menoret E, Dubljevic V, Menu E, Vanderkerken K, Lapa C, Steinbrunn T, Chatterjee M, Knop S, Düll J, Greenwood DL, Hensel F, Rosenwald A, Einsele H, Brändlein S.

Clin Cancer Res. 2016 Sep 1;22(17):4341-9. doi: 10.1158/1078-0432.CCR-15-3111. Epub 2016 Mar 30.

35.

Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy.

Dufait I, Van Valckenborgh E, Menu E, Escors D, De Ridder M, Breckpot K.

Oncotarget. 2016 Jul 5;7(27):42698-42715. doi: 10.18632/oncotarget.8311. Review.

36.

Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.

Wang J, De Veirman K, Faict S, Frassanito MA, Ribatti D, Vacca A, Menu E.

J Pathol. 2016 Jun;239(2):162-73. doi: 10.1002/path.4712. Epub 2016 Apr 7.

PMID:
26956697
37.

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

Favreau M, Vanderkerken K, Elewaut D, Venken K, Menu E.

Oncotarget. 2016 Apr 26;7(17):23128-40. doi: 10.18632/oncotarget.7440. Review.

38.

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.

Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Jan 26;7(4):4062-76. doi: 10.18632/oncotarget.6768.

39.

Novel strategies to target the ubiquitin proteasome system in multiple myeloma.

Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Feb 9;7(6):6521-37. doi: 10.18632/oncotarget.6658. Review.

40.

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.

Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E.

Oncotarget. 2015 Dec 22;6(41):43992-4004. doi: 10.18632/oncotarget.6083.

41.

Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.

Frassanito MA, De Veirman K, Desantis V, Di Marzo L, Vergara D, Ruggieri S, Annese T, Nico B, Menu E, Catacchio I, Ria R, Racanelli V, Maffia M, Angelucci E, Derudas D, Fumarulo R, Dammacco F, Ribatti D, Vanderkerken K, Vacca A.

Leukemia. 2016 Mar;30(3):640-8. doi: 10.1038/leu.2015.289. Epub 2015 Oct 21.

PMID:
26487273
42.

The local environment orchestrates mucosal decidual macrophage differentiation and substantially inhibits HIV-1 replication.

El Costa H, Quillay H, Marlin R, Cannou C, Duriez M, Benjelloun F, de Truchis C, Rahmati M, Ighil J, Barré-Sinoussi F, Nugeyre MT, Menu E.

Mucosal Immunol. 2016 May;9(3):634-46. doi: 10.1038/mi.2015.87. Epub 2015 Sep 9.

43.

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.

De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2015 Apr 30;6(12):10532-47.

44.

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E.

Oncotarget. 2015 Feb 20;6(5):3319-34.

45.

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.

De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA.

Front Oncol. 2014 Dec 8;4:349. doi: 10.3389/fonc.2014.00349. eCollection 2014. Review.

46.

Distinct characteristics of endometrial and decidual macrophages and regulation of their permissivity to HIV-1 infection by SAMHD1.

Quillay H, El Costa H, Marlin R, Duriez M, Cannou C, Chrétien F, Fernandez H, Lebreton A, Ighil J, Schwartz O, Barré-Sinoussi F, Nugeyre MT, Menu E.

J Virol. 2015 Jan 15;89(2):1329-39. doi: 10.1128/JVI.01730-14. Epub 2014 Nov 12.

47.

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.

Nur H, Rao L, Frassanito MA, De Raeve H, Ribatti D, Mfopou JK, Van Valckenborgh E, De Bruyne E, Vacca A, Vanderkerken K, Menu E.

Br J Haematol. 2014 Dec;167(5):651-63. doi: 10.1111/bjh.13092. Epub 2014 Aug 21.

PMID:
25142285
48.

Human decidual macrophages and NK cells differentially express Toll-like receptors and display distinct cytokine profiles upon TLR stimulation.

Duriez M, Quillay H, Madec Y, El Costa H, Cannou C, Marlin R, de Truchis C, Rahmati M, Barré-Sinoussi F, Nugeyre MT, Menu E.

Front Microbiol. 2014 Jul 1;5:316. doi: 10.3389/fmicb.2014.00316. eCollection 2014.

49.

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.

Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen HE, Overgaard MT, Larsson O, Axelson M, Nyegaard M, Schots R, Jernberg-Wiklund H, Vanderkerken K, De Bruyne E.

Oncotarget. 2014 Nov 30;5(22):11193-208.

50.

Cancer associated fibroblasts and tumor growth: focus on multiple myeloma.

De Veirman K, Rao L, De Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A, Vanderkerken K.

Cancers (Basel). 2014 Jun 27;6(3):1363-81. doi: 10.3390/cancers6031363.

Supplemental Content

Support Center